Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) EBT (2018 - 2025)

Bicycle Therapeutics (BCYC) has disclosed EBT for 8 consecutive years, with -$58.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT fell 8.56% year-over-year to -$58.9 million, compared with a TTM value of -$73.2 million through Sep 2025, up 57.76%, and an annual FY2024 reading of $5.8 million, up 103.18% over the prior year.
  • EBT was -$58.9 million for Q3 2025 at Bicycle Therapeutics, up from -$79.2 million in the prior quarter.
  • Across five years, EBT topped out at $126.7 million in Q4 2024 and bottomed at -$79.2 million in Q2 2025.
  • Average EBT over 5 years is -$29.5 million, with a median of -$30.4 million recorded in 2022.
  • The sharpest move saw EBT skyrocketed 341.05% in 2024, then crashed 129.78% in 2025.
  • Year by year, EBT stood at -$19.8 million in 2021, then tumbled by 53.15% to -$30.4 million in 2022, then plummeted by 72.88% to -$52.6 million in 2023, then surged by 341.05% to $126.7 million in 2024, then crashed by 146.49% to -$58.9 million in 2025.
  • Business Quant data shows EBT for BCYC at -$58.9 million in Q3 2025, -$79.2 million in Q2 2025, and -$61.8 million in Q1 2025.